Metabolon, a company whose technology is used in diagnostics and biochemical profiling, has closed on $15 million in new financing.
A total of 16 investors participated in the equity financing, according to securities filings. Metabolon raised the money quickly. The date of the first sale of securities for the Research Triangle Park-based company was Dec. 16.
Metabolon works in the field of metabolomics. The company’s proprietary platform technology can identify biochemical signatures at the cellular level. The technology has applications in the life sciences; in October Metabolon announced a marketing agreement with New York company Bostwick Laboratories establishing a path to commercialization for Metabolon’s prostate cancer test Prostarix.
Metabolon’s technology also has applications in food and nutrition. In July, Metabolon announced a research partnership with Spain-based IMDEA Food to find the links between nutrition and health at the molecular level. Food companies already employ the Metabolon platform to support research their health and nutrition claims.
